About This Fund
ARTIS TechBio II is a USD 200 million venture capital fund managed by ARTIS Ventures, a San Francisco-based firm founded in 2001 by Stuart Peterson. The fund closed on 14 December 2023 and is ARTIS Ventures' fourth fund overall and its second dedicated TechBio vehicle. ARTIS coined and trademarked the term TechBio to describe the convergence of technology and biology, and both TechBio funds operate under that exclusive mandate. Managing Partners Stuart Peterson and Vasudev Bailey lead the fund alongside Senior Partners Austin Walne and Ruchita Sinha.
The fund invests at seed through Series B stages — with typical check sizes ranging from USD 2 million to USD 15 million with reserves for follow-on — in companies using data science, software, artificial intelligence, machine learning, and synthetic biology to transform human health and well-being. Six operating principles guide portfolio construction: global-scale platforms, underserved disease areas, system-wide care delivery innovation, founder diversity (over 60% of portfolio founders from underrepresented groups), perseverance in regulated industries, and specialised healthcare expertise. Portfolio companies are required to address measurable patient outcomes or health system efficiency gaps, reflecting the fund's impact-aligned mandate.
The broader ARTIS Ventures platform spans TechBio I and II plus earlier general life sciences vehicles. Known portfolio companies across the platform include Freenome, Eko, Delix Therapeutics, Outpace Bio, Tessera Therapeutics, Rad AI, and Onto Health. ARTIS Ventures' exit track record includes Stemcentrx (acquired by AbbVie for approximately USD 10 billion), Lemonaid Health (acquired by 23andMe), YouTube (acquired by Google), Palantir (IPO), Aruba Networks (IPO), and Bloom Energy (IPO). TechBio II's early confirmed investments include Range Biotechnologies (seed, June 2023) and RightSite (January 2025), demonstrating active deployment across its life-sciences-meets-technology thesis.